Stock info Neurocrine Biosciences | Filter  Basic-Info

Neurocrine Biosciences

The past year gave good returns for Neurocrine Biosciences investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Neurocrine Biosciences, the stock lost around 21 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 443 percent. Neurocrine Biosciences's revenues between 2011 and 2015 were quite unstable and moved between 53,14 million dollars and 19,77 million dollars. During 2011 and 2015 Neurocrine Biosciences's net results were very volatile and fluctuated between 37,57 million dollars and -88,93 million dollars.

Neurocrine Biosciences is mostly active in the biotech sector. The past 10 years the (international) industry gained at around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

The American company didn't pay out any dividends (in the past 5 years).

Neurocrine Biosciences's balance mostly consists of debt

At the end of 2015 the American company's balance sheet was worth 474,79 million dollars. At the end of 2015 the total debt positon equaled 50,34 million dollars. This is around 10,6 percent of the total balance sheet. Last year the biotech company's price/earnings-ratio (PE) was around -21. So the investors valued the stock at -21 times 2015' earnings per share. Based on the classical stock valuation theories the American stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the biotech company equaled around 4,66 billion dollars. At the end of 2015 the American company had around 84,5 million stocks listed.

All Neurocrine Biosciences's annual reports can be found here. More information about Neurocrine Biosciences can be found it's website. .